Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 11;7(3):IJH04.
doi: 10.2217/ijh-2018-0001. eCollection 2018 Oct.

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives

Chetasi Talati  1 , Kendra L Sweet  1
Affiliations
Review

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives

Chetasi Talati et al. Int J Hematol Oncol. .

Abstract

Selective inhibitors of nuclear export (SINE) are emerging as a potentially efficacious therapeutic strategy for overcoming resistance to conventional chemotherapy for acute myeloid leukemia. SINE specifically block the protein Exportin 1, also known as chromosomal region maintenance 1, leading to nuclear retention of cargo proteins, including several tumor suppressor proteins. Selinexor, a first generation SINE, is currently in early phase clinical studies in various combinations with promising antileukemic and pro-apoptotic activity. Here we discuss the mechanism of action of SINEs and further elaborate on the clinical data available from the various trials in acute myeloid leukemia.

Keywords: CRM1 inhibitor; KPT-8602; XPO1 inhibitor; acute myeloid leukemia; nuclear transport inhibitor; selinexor.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure KL Sweet received honorarium and research funding from Karyopharm in 2016. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Mechanism of action of selective inhibitors of nuclear export.
See this image and copyright information in PMC

References

    1. Garg M, Nagata Y, Kanojia D, et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015;126(22):2491–2501. - PMC - PubMed
    1. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75(1):27–32. - PubMed
    1. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized Phase III study. J. Clin. Oncol. 2012;30(20):2441–2448. - PubMed
    1. Lowenberg B, Ossenkoppele GJ, Van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 2009;361(13):1235–1248. - PubMed
    1. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 2009;361(13):1249–1259. - PMC - PubMed

LinkOut - more resources